====Janux Therapeutics (JANX) : "positive" interim clinical data from Phase 1a Dose escalation for PSMA-TRACTr JANX007

 

Janux Therapeutics announces "positive" interim clinical data from Phase 1a Dose escalation for PSMA-TRACTr JANX007

• Multiple patients treated with PSMA-TRACTr JANX007 have achieved meaningful PSA drops coupled with manageable safety and CRS
• PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008 have been generally well tolerated at levels above the projected maximum tolerable dose of the parental T cell engagers
• JANX007 preliminary data showed encouraging safety results consistent with on-tumor activity with no dose-limiting toxicities
• PK exposure demonstrated TRACTr activation with lack of TCE accumulation
• No treatment-emergent ADA titers observed

Janux Therapeutics announces pricing of $60 million underwritten offering of common at a price of $12.46/share

• Co also announces pre-funded warrants are being sold at a price of $12.459 per pre-funded warrant, which represents the per share price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant.
• The gross proceeds from the offering to Janux are expected to be approximately $60 million, before deducting underwriting discounts and commissions and offering expenses.
• The offering is expected to close on or about July 19, 2023, subject to the satisfaction of customary closing conditions.